

Vimta Labs Limited

Registered Office
142, IDA Phase II, Cherlapally
Hyderabad-500 051, Telangana, India
T : +91 40 2726 4141
F : +91 40 2726 3657



VLL\SE\042\2023-24
Date: 28.07.2023

Listing Centre
B S E Limited
P J Towers, Dalal Street
Mumbai: 400001
Scrip Code No.524394

Asst Vice President
National Stock Exchange of India Limited
"Exchange Plaza", Bandra
Kurla Complex, Bandra (E)
Mumbai – 400051
Trading Symbol: VIMTALABS

Dear Sir/Madam,

Sub – Press Release – Unaudited Financial Results – 30th June 2023.

Pursuant to Regulation 30 of SEBI (Listing obligations and disclosure requirements) 2015, please find attached the press release in connection with announcement of unaudited Standalone and Consolidated Financial Results for the 1st Quarter ended 30th June 2023.

This is for your information and records.

Thanking you,

Yours faithfully,
for VIMTA LABS LIMITED

Sujani Vasireddi
Company Secretary

Attachments: as above.



Vimta Labs Limited Reports Q1 FY24 Results

**Q1FY24 Total Income at Rs. 841 Mn,
EBITDA margins steady at 30.0%; PAT margin at 14.5%**

Hyderabad, July 28, 2023: Vimta Labs Limited (VIMTA) (BSE: 524394, NSE: VIMTALABS), India's leading Contract Research and Testing Organisation, has announced its financial results for the quarter ended June 30, 2023.

Consolidated Financial Results – Q1 FY24

Particulars (Rs. Mn)	Q1FY24	Q1FY23	Q4FY23
Total Income	841	800	825
EBITDA (including other income)	252	248	248
EBITDA Margin	30.0%	31.0%	30.1%
PAT	122	120	127
PAT Margin	14.5%	15.0%	15.4%
Basic EPS	5.5	5.4	5.7

Commenting on results, Ms. Harita Vasireddi, Managing Director, Vimta Labs Limited, said: *"We are extremely pleased with the continued growth momentum despite a challenging external environment. During Q1FY24, our total income was at Rs. 841mn. Pharma segment led the growth during the quarter with food segment getting impacted due to Biparjoy cyclone whereas other segments remained stable.*

While the external environment remains uncertain, a robust demand in the TIC market gives us confidence of delivering strong growth in the coming quarters."

Key Results Highlights for the Q1FY24 (Consolidated):

- ✓ Total Income for Q1FY24 were at Rs. 841 Mn
- ✓ EBITDA for Q1FY24 was Rs. 252 Mn; EBITDA margin remained steady at 30.0%
- ✓ Q1FY24 PAT was at Rs. 122 Mn; PAT Margins for the quarter was at 14.5%
- ✓ Basic EPS was at Rs. 5.5 in Q1FY24 as against Rs. 5.4 in Q1FY23
- ✓ Total Debt as of 30th June 2023 stood at Rs. 137 Mn down from Rs. 150 Mn as of 31st March 2023
- ✓ Cash and Cash equivalents were at Rs. 285 Mn as of 30th June 2023
- ✓ Q1FY24 Capex was at Rs 218 Mn
- ✓ Debt to Equity ratio was 0.05x

ABOUT VIMTA LABS LIMITED:

Founded in 1984 with headquarters in Hyderabad, India, VIMTA LABS LTD., is a leading contract research and testing organization, providing food, agri, bio/pharmaceutical, medical device, speciality chemical, and electronics companies an integrated scientific, technical, and regulatory expertise to support all stages of product development and manufacturing process. Vimta also provides clinical diagnostic services and environmental assessments and testing services.

CAUTIONARY STATEMENT:

This press release may contain certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward-looking statements are subject to a number of known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward-looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Vimta Labs Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.

For details, please contact:

<p>Investor Relations at Vimta Labs Narahai Naidu Dodda, CFO Narahai.Dodda@vimta.com</p> <p>Ernst & Young Mr. Rahul Thakur Rahul.thakur@in.ey.com</p> <p>Mr. Advait Bhadekar Advait.bhadekar@in.ey.com</p>	<p>Registered Office Plot Number 142, IDA Phase 2 Cherlapally, Hyderabad Telangana, India. 500051 CIN: L24110TG1990PLC011977 ISIN: INE579C01029 NSE Code: VIMTALABS BSE CODE: 524394 Website: www.vimta.com</p>
--	---